Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study

MLA

Agnès Linglart, et al. “Effect of Krn23, a Fully Human Anti-Fgf23 Monoclonal Antibody, on Rickets in Children with X-Linked Hypophosphatemia (Xlh): 40-Week Interim Results from a Randomized, Open-Label Phase 2 Study.” Section on Advances in Therapeutics and Technology Program, Jan. 2018. EBSCOhost, https://doi.org/10.1542/peds.141.1_meetingabstract.264.

APA

Agnès Linglart, Javier San Martin, Raja Padidela, Thomas O. Carpenter, Annemieke Boot, Michael P. Whyte, Eric Imel, Wolfgang Högler, William van’t Hoff, & Anthony A. Portale. (2018). Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study. Section on Advances in Therapeutics and Technology Program. https://doi.org/10.1542/peds.141.1_meetingabstract.264

Chicago

Agnès Linglart, Javier San Martin, Raja Padidela, Thomas O. Carpenter, Annemieke Boot, Michael P. Whyte, Eric Imel, Wolfgang Högler, William van’t Hoff, and Anthony A. Portale. 2018. “Effect of Krn23, a Fully Human Anti-Fgf23 Monoclonal Antibody, on Rickets in Children with X-Linked Hypophosphatemia (Xlh): 40-Week Interim Results from a Randomized, Open-Label Phase 2 Study.” Section on Advances in Therapeutics and Technology Program, January. doi:10.1542/peds.141.1_meetingabstract.264.